Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Sarepta Therapeutics, Inc. (SRPT) had Stock-Based Compensation of $41.43M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$744.86M |
|
$-447.51M |
|
$137.56M |
|
$607.29M |
|
$1.05B |
|
$-300.39M |
|
$-83.13M |
|
$-383.52M |
|
$-383.52M |
|
$-447.51M |
|
$-447.51M |
|
$-447.51M |
|
$-447.51M |
|
$-300.39M |
|
$-292.32M |
|
97.36M |
|
97.36M |
|
$-4.60 |
|
$-4.60 |
|
| Balance Sheet Financials | |
$2.43B |
|
$360.59M |
|
$1.03B |
|
$3.47B |
|
$605.59M |
|
$1.14B |
|
$1.72B |
|
$2.32B |
|
$1.14B |
|
$1.14B |
|
$1.14B |
|
98.25M |
|
| Cash Flow Statement Financials | |
$-583.44M |
|
$-291.18M |
|
$12.47M |
|
$1.12B |
|
$256.45M |
|
$-862.14M |
|
|
Stock-Based Compensation |
$41.43M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.02 |
|
-- |
|
-- |
|
0.50 |
|
1.00 |
|
81.53% |
|
-40.33% |
|
-40.33% |
|
-- |
|
-51.49% |
|
-60.08% |
|
$-627.09M |
|
-- |
|
-- |
|
-- |
|
0.21 |
|
0.15 |
|
1.13 |
|
79.67 |
|
-39.16% |
|
-39.16% |
|
-12.91% |
|
-19.62% |
|
$11.63 |
|
$-6.44 |
|
$-5.99 |
|